HK1208818A1 - 雜芳基-酮稠合的氮萘烷糖皮質激素受體調節劑 - Google Patents

雜芳基-酮稠合的氮萘烷糖皮質激素受體調節劑

Info

Publication number
HK1208818A1
HK1208818A1 HK15109587.3A HK15109587A HK1208818A1 HK 1208818 A1 HK1208818 A1 HK 1208818A1 HK 15109587 A HK15109587 A HK 15109587A HK 1208818 A1 HK1208818 A1 HK 1208818A1
Authority
HK
Hong Kong
Prior art keywords
receptor modulators
glucocorticoid receptor
fused azadecalin
heteroaryl ketone
ketone fused
Prior art date
Application number
HK15109587.3A
Other languages
English (en)
Inventor
Hazel Hunt
Tony Johnson
Nicholas Ray
Iain Walters
Original Assignee
Corcept Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corcept Therapeutics Inc filed Critical Corcept Therapeutics Inc
Publication of HK1208818A1 publication Critical patent/HK1208818A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
HK15109587.3A 2012-05-25 2015-09-29 雜芳基-酮稠合的氮萘烷糖皮質激素受體調節劑 HK1208818A1 (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201261651669P 2012-05-25 2012-05-25
US201261691083P 2012-08-20 2012-08-20
US201261715907P 2012-10-19 2012-10-19
US201361759520P 2013-02-01 2013-02-01
US201361781629P 2013-03-14 2013-03-14
PCT/US2013/042732 WO2013177559A2 (en) 2012-05-25 2013-05-24 Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators

Publications (1)

Publication Number Publication Date
HK1208818A1 true HK1208818A1 (zh) 2016-03-18

Family

ID=49624542

Family Applications (2)

Application Number Title Priority Date Filing Date
HK15109587.3A HK1208818A1 (zh) 2012-05-25 2015-09-29 雜芳基-酮稠合的氮萘烷糖皮質激素受體調節劑
HK18109510.2A HK1250014B (zh) 2012-05-25 2018-07-23 雜芳基-酮稠合的氮萘烷糖皮質激素受體調節劑

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK18109510.2A HK1250014B (zh) 2012-05-25 2018-07-23 雜芳基-酮稠合的氮萘烷糖皮質激素受體調節劑

Country Status (22)

Country Link
EP (5) EP3338781B1 (zh)
JP (1) JP6172871B2 (zh)
KR (1) KR102062640B1 (zh)
CN (1) CN104619328B (zh)
AU (1) AU2013266110C1 (zh)
CA (1) CA2872260C (zh)
CL (1) CL2014003173A1 (zh)
DK (4) DK2854814T3 (zh)
ES (4) ES2665338T3 (zh)
HK (2) HK1208818A1 (zh)
IL (1) IL235868A (zh)
MX (1) MX365423B (zh)
MY (1) MY172739A (zh)
NZ (1) NZ701469A (zh)
PE (1) PE20150352A1 (zh)
PH (1) PH12014502584B1 (zh)
PL (4) PL2854814T3 (zh)
PT (4) PT3590517T (zh)
RU (1) RU2639867C2 (zh)
SG (1) SG11201407682TA (zh)
WO (1) WO2013177559A2 (zh)
ZA (1) ZA201408182B (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11925626B2 (en) 2018-12-19 2024-03-12 Corcept Therapeutics Incorporated Pharmaceutical formulations containing relacorilant, a heteroaryl-ketone fused azadecalin compound

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
ES2869172T3 (es) * 2013-11-25 2021-10-25 Corcept Therapeutics Inc Moduladores del receptor de glucocorticoides de azadecalina condensada con octahidro
WO2016140867A1 (en) * 2015-03-02 2016-09-09 Corcept Therapeutics, Inc. Use of glucocorticoid receptor antagonist and somatostatin analogues to treat acth-secreting tumors
CA2978960C (en) * 2015-03-30 2023-05-02 Corcept Therapeutics, Inc. Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency
IL309712A (en) 2015-05-18 2024-02-01 Corcept Therapeutics Inc Methods for diagnosing and determining treatment for Cushing's syndrome
EP3335043B1 (en) 2015-08-13 2021-03-31 Corcept Therapeutics, Inc. Method for differentially diagnosing acth-dependent cushing's syndrome
EP3423453A4 (en) * 2016-03-01 2019-11-06 Corcept Therapeutics, Inc. USE OF GLUCOCORTICOID RECEPTOR MODULATORS TO POTENTIATE CONTROL POINT INHIBITORS
US9943505B2 (en) * 2016-09-09 2018-04-17 Corcept Therapeutics, Inc. Glucocorticoid receptor modulators to treat pancreatic cancer
EP3600282A4 (en) 2017-03-31 2020-08-19 Corcept Therapeutics, Inc. GLUCOCORTICOID RECEPTOR MODULATORS FOR THE TREATMENT OF COLD CANCER
CA3065555A1 (en) 2017-06-20 2018-12-27 Corcept Therapeutics, Inc. Methods of treating neuroepithelial tumors using selective glucocorticoid receptor modulators
AU2019261274B2 (en) * 2018-04-23 2021-10-28 Corcept Therapeutics, Inc. Methods of preparing regioselective N-alkyl triazoles
EP3876936A4 (en) * 2018-11-09 2022-08-17 Corcept Therapeutics Incorporated PROCEDURE FOR SHRINKING PITITUNITIAL TUMORS
US11234971B2 (en) 2018-12-19 2022-02-01 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
US11389432B2 (en) 2018-12-19 2022-07-19 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
EP3897629A4 (en) 2018-12-20 2022-12-07 Corcept Therapeutics Incorporated METHODS FOR IMAGING AND TREATING SOMATOSTATIN RECEPTOR POSITIVE TUMORS
BR112021015129A2 (pt) * 2019-02-22 2021-09-28 Corcept Therapeutics Incorporated Método para tratar um paciente que sofre de hipercortisolemia e um sintoma ou comorbidade da mesma
EP4045045A4 (en) * 2019-10-16 2023-11-22 Corcept Therapeutics Incorporated METHOD FOR NORMALIZING THE RATIO OF NEUTROPHILS TO LYMPHOCYTES IN CANCER PATIENTS USING A SELECTIVE GLUCOCORTICOID RECEPTOR ANTAGONIST
JP2023505948A (ja) 2019-12-11 2023-02-14 コーセプト セラピューティクス， インコーポレイテッド 抗精神病薬誘発性体重増加のミリコリラントによる治療方法
WO2021127376A1 (en) * 2019-12-21 2021-06-24 Corcept Therapeutics Incorporated Treatment of, and differential diagnosis between, acth-dependent cushing's syndrome and acth-independent cushing's syndrome
WO2022134033A1 (en) * 2020-12-25 2022-06-30 Corcept Therapeutics Incorporated Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
CN116829556A (zh) * 2021-02-03 2023-09-29 江苏恒瑞医药股份有限公司 稠合的氮杂三环类衍生物、其制备方法及其在医药上的应用
WO2024077169A1 (en) * 2022-10-06 2024-04-11 Corcept Therapeutics Incorporated Formulations of glucocorticoid receptor modulators

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4391904A (en) 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
GB8828669D0 (en) * 1988-12-08 1989-01-11 Lilly Industries Ltd Organic compounds
ES2313317T3 (es) * 2004-03-09 2009-03-01 Corcept Therapeutics, Inc. Moduladores del receptor de glucocorticoides de azadecalina de anillo condensado.
US7640389B2 (en) * 2006-02-28 2009-12-29 Freescale Semiconductor, Inc. Non-volatile memory having a multiple block erase mode and method therefor
EP1932843A1 (en) * 2006-12-14 2008-06-18 sanofi-aventis Sulfonyl-phenyl-2H-(1,2,4) oxadiazole-5-one derivatives, processes for their preparation and their use as pharmaceuticals
JP2013536250A (ja) * 2010-08-27 2013-09-19 コーセプト セラピューティクス， インコーポレイテッド ピリジル−アミン縮合アザデカリンモジュレーター

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11925626B2 (en) 2018-12-19 2024-03-12 Corcept Therapeutics Incorporated Pharmaceutical formulations containing relacorilant, a heteroaryl-ketone fused azadecalin compound

Also Published As

Publication number Publication date
EP3590517A1 (en) 2020-01-08
PT3590517T (pt) 2021-04-07
EP3338781B1 (en) 2019-09-11
EP3338781A1 (en) 2018-06-27
EP3851107B1 (en) 2022-10-19
EP3851107A1 (en) 2021-07-21
RU2639867C2 (ru) 2017-12-25
EP4119561A1 (en) 2023-01-18
PH12014502584A1 (en) 2015-01-21
JP6172871B2 (ja) 2017-08-02
SG11201407682TA (en) 2014-12-30
AU2013266110C1 (en) 2018-07-12
WO2013177559A3 (en) 2014-01-16
PL3338781T3 (pl) 2020-03-31
PE20150352A1 (es) 2015-03-16
EP2854814A4 (en) 2016-01-27
CA2872260C (en) 2020-12-22
HK1250014B (zh) 2020-06-12
NZ701469A (en) 2017-06-30
DK2854814T3 (en) 2018-03-12
KR20150021955A (ko) 2015-03-03
CL2014003173A1 (es) 2015-02-27
MY172739A (en) 2019-12-11
ES2930298T3 (es) 2022-12-09
JP2015517580A (ja) 2015-06-22
EP2854814A2 (en) 2015-04-08
WO2013177559A2 (en) 2013-11-28
CN104619328B (zh) 2018-10-02
EP3590517B1 (en) 2021-03-17
PT3851107T (pt) 2022-10-28
PT3338781T (pt) 2019-11-29
IL235868A0 (en) 2015-01-29
RU2014152625A (ru) 2016-07-20
PH12014502584B1 (en) 2015-01-21
DK3590517T3 (da) 2021-05-03
MX365423B (es) 2019-06-03
PL3590517T3 (pl) 2021-09-20
EP2854814B1 (en) 2018-01-31
ES2873949T3 (es) 2021-11-04
CN104619328A (zh) 2015-05-13
AU2013266110A1 (en) 2014-11-20
AU2013266110B2 (en) 2017-04-20
PL3851107T3 (pl) 2023-03-06
PL2854814T3 (pl) 2018-07-31
ZA201408182B (en) 2017-09-27
IL235868A (en) 2017-12-31
ES2665338T3 (es) 2018-04-25
DK3338781T3 (da) 2019-12-09
ES2753816T3 (es) 2020-04-14
MX2014014239A (es) 2015-08-05
DK3851107T3 (da) 2022-11-21
CA2872260A1 (en) 2013-11-28
KR102062640B1 (ko) 2020-01-06
PT2854814T (pt) 2018-03-15

Similar Documents

Publication Publication Date Title
HK1250014B (zh) 雜芳基-酮稠合的氮萘烷糖皮質激素受體調節劑
ZA201604026B (en) Octahydro fused azadecalin glucocorticoid receptor modulators
EP2609097A4 (en) AZADECALINE PYRIDYL-AMINE MODULATORS
HK1223353A1 (zh) 受體調節劑
HK1209744A1 (zh) 新的選擇性雄激素受體調節劑
IL235557A0 (en) Modulators of 17 gpr receptors
EP2935284A4 (en) HETEROCYCLIC MODULATORS OF HORMONE NUCLEAR RECEPTORS
HUE049728T2 (hu) Benzofurán-2-szulfonamid származékok, mint kemokin receptor modulátorok
EP2892527A4 (en) HETEROCYCLIC MODULATORS OF NUCLEAR HORMONAL RECEPTORS